ITGR resets its 2026 outlook after customer forecast changes and slower product ramps, with growth and margin recovery tied to adoption timing.
Integer Holdings Corp. is a unique, high-quality medical device CDMO trading at a depressed ~10x EBITDA multiple after a temporary growth slowdown. A strategic review, prompted by activist involvement and heightened buyer interest, positions ITGR for a likely sale within three to four months. Precedent CDMO transactions support a fair value of $110–125/share (13–14x forward EBITDA), offering 20–40% upside with limited downside risk.
Integer Holdings Corporation (ITGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Integer's shares jump despite a Q1 EPS miss and margin pressure, as revenues rise slightly Y/Y and beat estimates on strength across key product lines.
Integer Holdings Corporation (ITGR) Q1 2026 Earnings Call Transcript
The headline numbers for Integer (ITGR) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integer (ITGR) came out with quarterly earnings of $1.2 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.31 per share a year ago.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ITGR's strong product sales and R&D momentum support growth outlook, but near-term product adoption delays and margin pressure remain key risks.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.